Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Giuseppe Curigliano, MD, PhD, is Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where he is also a clinician and researcher specializing in breast cancer. Dr Curigliano earned his MD at the Universita’ Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993–1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995–96). This work experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection. He moved to the European Institute of Oncology in 1999. He applied his strong basic science background to his clinical research, leading several translational research protocols on breast and urogenital cancer. He worked on the phase I unit for three years, contributing to successful development of several targeted agents and cytotoxics. Since 2001 he has been assistant professor of clinical pharmacology at the University of Milan. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is Co-Chair of the Division of Clinical Oncology, coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). His clinical experience is based on a daily clinical management of patients with solid tumors, within a comprehensive cancer center accepting at least 85,000 first diagnosis patients every year. He practices in the inpatient, outpatient and day hospital setting. He served for 3 years on the emergency and palliative care section of the Division. He is an active member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is the founding member and scientific coordinator of the International Cardio-Oncology Society (ICOS). He serves on the Clinical Research Committee of the AIOM. He serves as a faculty member in the European School of Oncology (ESO). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference in 2009, 2011 and 2013 as scientific secretary. From October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference 2013 and served ad Chair of the metastatic breast cancer track for ESMO 2014 meeting in Madrid.
Dr Curigliano's research experience includes principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has also been involved as Principal Investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the Coordinator of a research platform on new drug development in breast cancer at the European Institute of Oncology. Dr Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 160 peer reviewed article, most of them as first author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute, the European Journal of Cancer and many other “breast oriented journals”. He is a member of the Editorial Boards of the Journal of Clinical Oncology and Annals of Oncology. He serves in the press committee of the European Society of Medical Oncology as Spokesperson Coordinator for breast cancer.
Marc Sanson, MD, PhD is Professor at P&M Curie University, Department of Neurology and Neuro-oncology, Pitié-Salpêtrière Hospital, in Paris, France.
Dr Sanson has published numerous research articles on neuro-oncology, including more than 100 papers dedicated to gliomas, as well as book chapters, and is a frequently requested lecturer on this topic. His main interest is focused on clinical and translational research on gliomas, including novel therapies, genetic alterations and new biomarkers.
He is a reviewer on a number of journals, including the Journal of Clinical Oncology, Lancet, Annals of Neurology, Neurology, Cancer, Clinical Cancer Research, and Cancer Research.
Dr Sanson earned his MD at University R Descartes and his PhD at University D Diderot, both in Paris. He completed a residency in Neurology in Paris, and a post-doc at McGill University, Canada.
Miguel A. Sanz
Miguel A. Sanz is Head of the Department of Hematology and Bone Marrow Transplant Unit at the University Hospital La Fe in Valencia, Spain, as well as associate professor of medicine at the University of Valencia. After earning his medical degree at the University of Salamanca in Spain, he was an intern, a resident and subsequently completed a fellowship in Hematology at the University Hospital La Fe. Professor Sanz is Chairman of the Spanish PETHEMA Group and of the Working Parties of Acute Promyelocytic Leukemia, Acute Myeloid Leukemia and Infections in Neutropenic Patients. He is currently a reviewer for numerous high-profile medical journals, and has authored more than 400 papers, 80 book chapters, and in excess of 950 abstracts at national and international meetings.